Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Mar 21, 2018 at 9:45 AM EDT

Prothena Climbs on Celgene Collaboration

This collaboration with Celgene looks like a chance for Prothena to really shine, especially considering that it has had a…

Chris Lange | Mar 20, 2018 at 12:30 PM EDT

FDA Looks to Crack Down on Menthol Cigarettes and Maybe More

Smoking seems to be the next hot topic with the FDA, with the agency considering banning or restricting menthol and…

Chris Lange | Mar 20, 2018 at 11:10 AM EDT

Arena Pharmaceuticals Wins Big in Midstage Trial

Arena Pharmaceuticals shares climbed early on Tuesday after the firm announced positive midstage results from its Phase 2 trial for…

Chris Lange | Mar 19, 2018 at 12:25 PM EDT

Cidara Therapeutics Sinks Despite Positive Midstage Results

Cidara Therapeutics shares took a big step back on Monday, despite the firm reporting positive topline results from its Phase…

Chris Lange | Mar 17, 2018 at 7:55 AM EDT

Even More Biopharma Catalysts Coming Through the End of March

Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates…

Lee Jackson | Mar 16, 2018 at 10:50 AM EDT

JPMorgan Has 3 Top Biotechnology Picks With Huge Upside Potential

These three top companies have solid catalyst potential and already have shown good clinical results on their leading assets.

Chris Lange | Mar 15, 2018 at 12:25 PM EDT

Alexion Wins Big in Late-Stage Trial

Alexion Pharmaceuticals watched its shares make a solid gain on Thursday after the firm announced positive results from its late-stage…

Lee Jackson | Mar 15, 2018 at 10:55 AM EDT

RBC Says 4 Health Care Stocks Are Potential 2018 Buyout Candidates

It happens every year, and 2018 won’t be any different. Larger companies looking to add to growth, beyond that of…

Chris Lange | Mar 15, 2018 at 10:25 AM EDT

Why Solid Biosciences Is Under Fire From the FDA

Solid Biosciences Inc. (NASDAQ: SLDB) watched its shares get crushed on Thursday after the company announced some complications with the…

Lee Jackson | Mar 15, 2018 at 9:40 AM EDT

Analyst Has 4 Favorite Biotechnology Stocks to Buy Now

A new Merrill Lynch research report makes the case that four top biotech companies the firm covers have some powerful…

Chris Lange | Mar 14, 2018 at 1:20 PM EDT

Elizabeth Holmes and Theranos Charged With Massive Fraud

The SEC has finally charged Silicon Valley-based private company Theranos, along with its founder and CEO Elizabeth Holmes and former…

Chris Lange | Mar 13, 2018 at 10:05 AM EDT

Bellicum Bounces With Cancer Drug Data

Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) shares made a solid gain on Tuesday after the company announced interim clinical data of…

Chris Lange | Mar 13, 2018 at 8:45 AM EDT

Why Proteostasis Therapeutics Shares Are Skyrocketing

Proteostasis Therapeutics saw its shares skyrocket going into Tuesday’s session following a pivotal decision from the FDA for the firm’s…

Chris Lange | Mar 12, 2018 at 11:05 AM EDT

Is Anthera Dead in the Water?

Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) saw its shares get absolutely crushed in Monday’s session following missed results in a late-stage…

Chris Lange | Mar 12, 2018 at 9:45 AM EDT

Major Biotechs: Tough Call for Short Sellers

The February 28 short interest data have been compared with the previous report, and short interest moves in the selected…

1 … 139 140 141 142 143 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Prothena Climbs on Celgene Collaboration

FDA Looks to Crack Down on Menthol Cigarettes and Maybe More

Arena Pharmaceuticals Wins Big in Midstage Trial

Cidara Therapeutics Sinks Despite Positive Midstage Results

Even More Biopharma Catalysts Coming Through the End of March

JPMorgan Has 3 Top Biotechnology Picks With Huge Upside Potential

Alexion Wins Big in Late-Stage Trial

RBC Says 4 Health Care Stocks Are Potential 2018 Buyout Candidates

Why Solid Biosciences Is Under Fire From the FDA

Analyst Has 4 Favorite Biotechnology Stocks to Buy Now

Elizabeth Holmes and Theranos Charged With Massive Fraud

Bellicum Bounces With Cancer Drug Data

Why Proteostasis Therapeutics Shares Are Skyrocketing

Is Anthera Dead in the Water?

Major Biotechs: Tough Call for Short Sellers

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Health and Healthcare Articles

All Health and Healthcare Articles

Prothena Climbs on Celgene Collaboration

FDA Looks to Crack Down on Menthol Cigarettes and Maybe More

Arena Pharmaceuticals Wins Big in Midstage Trial

Cidara Therapeutics Sinks Despite Positive Midstage Results

Even More Biopharma Catalysts Coming Through the End of March

JPMorgan Has 3 Top Biotechnology Picks With Huge Upside Potential

Alexion Wins Big in Late-Stage Trial

RBC Says 4 Health Care Stocks Are Potential 2018 Buyout Candidates

Why Solid Biosciences Is Under Fire From the FDA

Analyst Has 4 Favorite Biotechnology Stocks to Buy Now

Elizabeth Holmes and Theranos Charged With Massive Fraud

Bellicum Bounces With Cancer Drug Data

Why Proteostasis Therapeutics Shares Are Skyrocketing

Is Anthera Dead in the Water?

Major Biotechs: Tough Call for Short Sellers

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how